“Overview of the Safety Profile From Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 1, Jan. 2024, p. s344, https://doi.org/10.25251/skin.8.supp.344.